These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 18654610

  • 1. Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors.
    Gao Y, Whitaker-Dowling P, Griffin JA, Barmada MA, Bergman I.
    Cancer Gene Ther; 2009 Jan; 16(1):44-52. PubMed ID: 18654610
    [Abstract] [Full Text] [Related]

  • 2. Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu.
    Bergman I, Griffin JA, Gao Y, Whitaker-Dowling P.
    Int J Cancer; 2007 Jul 15; 121(2):425-30. PubMed ID: 17354238
    [Abstract] [Full Text] [Related]

  • 3. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM.
    Cancer Res; 2001 Feb 01; 61(3):880-3. PubMed ID: 11221874
    [Abstract] [Full Text] [Related]

  • 4. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
    Gao Y, Bergman I.
    J Virol; 2023 Jun 29; 97(6):e0037223. PubMed ID: 37199666
    [Abstract] [Full Text] [Related]

  • 5. Preferential targeting of vesicular stomatitis virus to breast cancer cells.
    Bergman I, Whitaker-Dowling P, Gao Y, Griffin JA.
    Virology; 2004 Dec 05; 330(1):24-33. PubMed ID: 15527831
    [Abstract] [Full Text] [Related]

  • 6. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y, Morrison BJ, Burke JD, Park JM, Terabe M, Janik JE, Forni G, Berzofsky JA, Morris JC.
    Cancer Res; 2004 Nov 01; 64(21):8022-8. PubMed ID: 15520211
    [Abstract] [Full Text] [Related]

  • 7. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y.
    Clin Cancer Res; 2009 Jul 15; 15(14):4612-21. PubMed ID: 19584156
    [Abstract] [Full Text] [Related]

  • 8. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
    Dela Cruz JS, Morrison SL, Penichet ML.
    Vaccine; 2005 Sep 15; 23(39):4793-803. PubMed ID: 15967544
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
    Chin CS, Graham LJ, Hamad GG, George KR, Bear HD.
    J Surg Res; 2001 Jun 15; 98(2):108-15. PubMed ID: 11397126
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
    Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW.
    Clin Cancer Res; 2005 Jun 15; 11(12):4533-44. PubMed ID: 15958639
    [Abstract] [Full Text] [Related]

  • 13. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.
    Triulzi C, Vertuani S, Curcio C, Antognoli A, Seibt J, Akusjärvi G, Wei WZ, Cavallo F, Kiessling R.
    Cancer Res; 2010 Oct 01; 70(19):7431-41. PubMed ID: 20823150
    [Abstract] [Full Text] [Related]

  • 14. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors.
    Tegerstedt K, Lindencrona JA, Curcio C, Andreasson K, Tullus C, Forni G, Dalianis T, Kiessling R, Ramqvist T.
    Cancer Res; 2005 Jul 01; 65(13):5953-7. PubMed ID: 15994974
    [Abstract] [Full Text] [Related]

  • 15. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
    Takeda K, Kojima Y, Uno T, Hayakawa Y, Teng MW, Yoshizawa H, Yagita H, Gejyo F, Okumura K, Smyth MJ.
    J Immunol; 2010 May 15; 184(10):5493-501. PubMed ID: 20400706
    [Abstract] [Full Text] [Related]

  • 16. Elimination of CD4+ T cells may overcome suppression of anti-HER2 immune responses in tumor-bearing hosts.
    Ishihara M, Tawara I, Wang L, Takahashi Y, Shiku H.
    Int J Oncol; 2003 May 15; 22(5):1135-9. PubMed ID: 12684682
    [Abstract] [Full Text] [Related]

  • 17. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine.
    Orlandi F, Venanzi FM, Concetti A, Yamauchi H, Tiwari S, Norton L, Wolchok JD, Houghton AN, Gregor PD.
    Clin Cancer Res; 2007 Oct 15; 13(20):6195-203. PubMed ID: 17947487
    [Abstract] [Full Text] [Related]

  • 18. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
    Wang H, Wei H, Zhang R, Hou S, Li B, Qian W, Zhang D, Kou G, Dai J, Guo Y.
    Clin Cancer Res; 2009 Feb 01; 15(3):943-50. PubMed ID: 19188165
    [Abstract] [Full Text] [Related]

  • 19. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response.
    Cho HM, Rosenblatt JD, Tolba K, Shin SJ, Shin DS, Calfa C, Zhang Y, Shin SU.
    Cancer Res; 2010 Dec 15; 70(24):10121-30. PubMed ID: 21159634
    [Abstract] [Full Text] [Related]

  • 20. [Chimeric T cell receptor N29gamma redirect T lymphocytes response specific to p185HER2 in A murine model of metastatic breast cancer].
    Li SP, Urban FA, Macgregor JN, Hughes DP, McDonagh KT.
    Ai Zheng; 2004 Nov 15; 23(11 Suppl):1370-5. PubMed ID: 15566639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.